BRPI0715888A2 - composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quente - Google Patents
composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quenteInfo
- Publication number
- BRPI0715888A2 BRPI0715888A2 BRPI0715888-2A2A BRPI0715888A BRPI0715888A2 BR PI0715888 A2 BRPI0715888 A2 BR PI0715888A2 BR PI0715888 A BRPI0715888 A BR PI0715888A BR PI0715888 A2 BRPI0715888 A2 BR PI0715888A2
- Authority
- BR
- Brazil
- Prior art keywords
- warm
- cancer
- blooded animal
- compound
- effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82331106P | 2006-08-23 | 2006-08-23 | |
US60/823,311 | 2006-08-23 | ||
US93877607P | 2007-05-18 | 2007-05-18 | |
US60/938,776 | 2007-05-18 | ||
PCT/GB2007/003179 WO2008023161A1 (en) | 2006-08-23 | 2007-08-21 | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0715888A2 true BRPI0715888A2 (pt) | 2013-09-17 |
BRPI0715888A8 BRPI0715888A8 (pt) | 2018-04-17 |
BRPI0715888B1 BRPI0715888B1 (pt) | 2021-11-03 |
Family
ID=38537521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715888-2A BRPI0715888B1 (pt) | 2006-08-23 | 2007-08-21 | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
Country Status (29)
Country | Link |
---|---|
US (6) | US7902189B2 (pt) |
EP (1) | EP2057156B1 (pt) |
JP (2) | JP5227321B2 (pt) |
KR (1) | KR101438245B1 (pt) |
AR (1) | AR062503A1 (pt) |
AU (1) | AU2007287430B2 (pt) |
BR (1) | BRPI0715888B1 (pt) |
CA (1) | CA2659851C (pt) |
CL (1) | CL2007002448A1 (pt) |
CO (1) | CO6150164A2 (pt) |
CY (1) | CY1119381T1 (pt) |
DK (1) | DK2057156T3 (pt) |
ES (1) | ES2648388T3 (pt) |
HR (1) | HRP20170627T1 (pt) |
HU (1) | HUE033894T2 (pt) |
IL (1) | IL196775A (pt) |
LT (1) | LT2057156T (pt) |
MX (1) | MX2009001946A (pt) |
MY (1) | MY148688A (pt) |
NO (1) | NO342383B1 (pt) |
NZ (1) | NZ575672A (pt) |
PL (1) | PL2057156T3 (pt) |
PT (1) | PT2057156T (pt) |
RS (1) | RS55881B1 (pt) |
RU (1) | RU2445312C2 (pt) |
SA (1) | SA07280461B1 (pt) |
SI (1) | SI2057156T1 (pt) |
TW (1) | TWI406863B (pt) |
WO (1) | WO2008023161A1 (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69638122D1 (de) * | 1996-09-04 | 2010-03-18 | Intertrust Tech Corp | Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung |
DK2057156T3 (en) * | 2006-08-23 | 2017-05-08 | Kudos Pharm Ltd | 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS |
KR20100089082A (ko) * | 2007-10-15 | 2010-08-11 | 아스트라제네카 아베 | 조합 059 |
JP2011512395A (ja) * | 2008-02-21 | 2011-04-21 | アストラゼネカ アクチボラグ | 組合せ療法238 |
MY172107A (en) * | 2008-06-20 | 2019-11-14 | Astrazeneca Ab | Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines |
UA101676C2 (uk) * | 2008-07-31 | 2013-04-25 | Дженентек, Инк. | Піримідинові сполуки, композиції і способи застосування |
BRPI0917540A2 (pt) | 2008-08-05 | 2015-11-17 | Daiichi Sankyo Co Ltd | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
ES2548141T3 (es) | 2008-11-20 | 2015-10-14 | Glaxosmithkline Llc | Compuestos químicos |
ES2570456T3 (es) * | 2009-02-12 | 2016-05-18 | Merck Serono Sa | 2-Morfolino-pirido[3,2-d]pirimidinas |
EP2427174A4 (en) * | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
JP5572715B2 (ja) | 2009-11-12 | 2014-08-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法 |
KR101469334B1 (ko) | 2009-11-12 | 2014-12-04 | 에프. 호프만-라 로슈 아게 | N-9-치환된 퓨린 화합물, 조성물 및 사용 방법 |
WO2011062939A1 (en) | 2009-11-18 | 2011-05-26 | Novartis Ag | Methods and compositions for treating solid tumors and other malignancies |
WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
CN102821767A (zh) | 2010-02-03 | 2012-12-12 | 西格诺药品有限公司 | Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定 |
EP2552428A1 (en) | 2010-03-30 | 2013-02-06 | Novartis AG | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ |
CN103080107A (zh) | 2010-06-25 | 2013-05-01 | 诺瓦提斯公司 | 作为蛋白激酶抑制剂的杂芳基化合物和组合物 |
SI2651951T1 (sl) | 2010-12-16 | 2015-01-30 | F. Hoffmann-La Roche Ag | Tricikliäśne p13k inhibitorske spojine in postopki uporabe |
WO2013003801A2 (en) | 2011-06-29 | 2013-01-03 | The Trustees Of Columbia University In The City Of New York | Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction |
MX2014001246A (es) | 2011-08-03 | 2014-06-11 | Signal Pharm Llc | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. |
CN105062961A (zh) | 2012-05-23 | 2015-11-18 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
MX2015004016A (es) * | 2012-09-28 | 2016-02-18 | Ignyta Inc | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
WO2014114928A1 (en) | 2013-01-23 | 2014-07-31 | Astrazeneca Ab | Chemical compounds |
EP2968317A4 (en) * | 2013-03-15 | 2016-12-28 | Univ Columbia | TARGETING OF THE MTOR PATH IN NEUROLOGICAL DISEASES |
CN105392499B (zh) | 2013-04-17 | 2018-07-24 | 西格诺药品有限公司 | 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法 |
WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
UA119538C2 (uk) | 2013-04-17 | 2019-07-10 | Сігнал Фармасьютікалз, Елелсі | Лікування злоякісної пухлини дигідропіразинопіразинами |
AU2014254058B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer |
AU2014254050B2 (en) | 2013-04-17 | 2018-10-04 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
JP2016516818A (ja) | 2013-04-17 | 2016-06-09 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びn−(3−(5−フルオロ−2−(4−(2−メトキシエトキシ)フェニルアミノ)ピリミジン−4−イルアミノ)フェニル)アクリルアミドを含む組合せ療法 |
US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
EP3360875A1 (en) | 2013-05-28 | 2018-08-15 | Astrazeneca AB | Chemical compounds |
CN109503591B (zh) | 2013-05-29 | 2022-03-01 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
CN106008559B (zh) * | 2015-03-25 | 2020-10-16 | 中国科学院上海药物研究所 | 取代吡啶并嘧啶类化合物的合成工艺 |
WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
DK3889145T3 (da) * | 2015-12-17 | 2024-03-18 | Merck Patent Gmbh | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme |
WO2017182495A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
MX2019013031A (es) | 2017-05-02 | 2020-08-03 | Revolution Medicines Inc | Análogos de rapamicina como inhibidores de mtor. |
CA3067585A1 (en) | 2017-06-22 | 2018-12-27 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
JP7340519B2 (ja) * | 2017-11-06 | 2023-09-07 | メッドシャイン ディスカバリー インコーポレイテッド | mTORC1/2二重阻害剤としてのピリドピリミジン系化合物 |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
US11471459B2 (en) | 2018-03-26 | 2022-10-18 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Compounds with enhanced anti-tumor effects |
WO2019212990A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
JP2022500384A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
MX2021004775A (es) | 2018-11-05 | 2021-06-08 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt). |
CN113286594B (zh) * | 2019-01-18 | 2023-12-15 | 南京明德新药研发有限公司 | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 |
CN113825760B (zh) * | 2019-05-06 | 2022-08-19 | 南京明德新药研发有限公司 | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 |
WO2021133509A1 (en) * | 2019-12-27 | 2021-07-01 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as mtor inhibitors |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
WO2021226135A1 (en) | 2020-05-04 | 2021-11-11 | Amgen Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
WO2021247859A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Pyridopyrimidines and methods of their use |
CA3207998A1 (en) | 2021-02-16 | 2022-08-25 | Geoffrey M. Lynn | Self-assembling nanoparticles based on amphiphilic peptides |
KR20240026911A (ko) * | 2021-05-04 | 2024-02-29 | 비질 뉴로사이언스 인코포레이티드 | 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법 |
WO2023107592A1 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Pyridopyrimidines and methods of their use |
WO2024092030A1 (en) | 2022-10-25 | 2024-05-02 | Vaccitech North America, Inc. | Self-assembling nanoparticles |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4832899A (pt) | 1971-08-28 | 1973-05-02 | ||
US4560685A (en) | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
WO1996035985A1 (fr) | 1995-05-10 | 1996-11-14 | Nintendo Co., Ltd. | Systeme de traitement de l'image dans lequel une manette analogique est utilisee |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CZ291386B6 (cs) * | 1996-02-13 | 2003-02-12 | Zeneca Limited | Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
NZ331191A (en) * | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
DK0961780T3 (da) * | 1997-02-12 | 2007-08-27 | Electrophoretics Ltd | Proteinmarkörer for lungecancer og anvendelse deraf |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
GB9900334D0 (en) * | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
US7074800B1 (en) * | 1999-02-10 | 2006-07-11 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
DE50008690D1 (de) | 1999-09-07 | 2004-12-23 | Syngenta Participations Ag | p-Tolyl-Heterocyclen als Herbizide |
CN101219145A (zh) | 1999-11-05 | 2008-07-16 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
JP4186355B2 (ja) * | 1999-11-24 | 2008-11-26 | 株式会社デンソー | Csma方式対応無線lan用アンテナ装置及び端末局 |
DE122008000002I1 (de) * | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
MXPA02011770A (es) * | 2000-05-31 | 2003-04-10 | Astrazeneca Ab | Derivados de indol con actividad de dano vascular. |
AU2001266232B2 (en) | 2000-07-07 | 2005-09-15 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
DK1575951T3 (da) | 2002-12-06 | 2014-09-15 | Debiopharm Int Sa | Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi |
ES2290743T3 (es) | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
GB0428475D0 (en) | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
JP2008531538A (ja) * | 2005-02-25 | 2008-08-14 | クドス ファーマシューティカルズ リミテッド | 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用 |
MX2007010404A (es) * | 2005-02-25 | 2008-01-11 | Kudos Pharm Ltd | Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer. |
CA2612788A1 (en) | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
JP5058991B2 (ja) | 2005-06-29 | 2012-10-24 | コンプメディクス リミテッド | 導電ブリッジを備えるセンサ・アセンブリ |
US20090169472A1 (en) * | 2005-10-12 | 2009-07-02 | Cancer Research Technology Ltd. | Methods and compositions for treating immune disorders |
JP5161102B2 (ja) * | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
DK2057156T3 (en) * | 2006-08-23 | 2017-05-08 | Kudos Pharm Ltd | 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS |
-
2007
- 2007-08-21 DK DK07789277.6T patent/DK2057156T3/en active
- 2007-08-21 HU HUE07789277A patent/HUE033894T2/en unknown
- 2007-08-21 PT PT77892776T patent/PT2057156T/pt unknown
- 2007-08-21 SI SI200731917A patent/SI2057156T1/sl unknown
- 2007-08-21 NZ NZ575672A patent/NZ575672A/en not_active IP Right Cessation
- 2007-08-21 WO PCT/GB2007/003179 patent/WO2008023161A1/en active Application Filing
- 2007-08-21 LT LTEP07789277.6T patent/LT2057156T/lt unknown
- 2007-08-21 AU AU2007287430A patent/AU2007287430B2/en active Active
- 2007-08-21 MY MYPI20090704A patent/MY148688A/en unknown
- 2007-08-21 RU RU2009110261/04A patent/RU2445312C2/ru active
- 2007-08-21 EP EP07789277.6A patent/EP2057156B1/en active Active
- 2007-08-21 PL PL07789277T patent/PL2057156T3/pl unknown
- 2007-08-21 RS RS20170417A patent/RS55881B1/sr unknown
- 2007-08-21 ES ES07789277.6T patent/ES2648388T3/es active Active
- 2007-08-21 CA CA2659851A patent/CA2659851C/en active Active
- 2007-08-21 JP JP2009525105A patent/JP5227321B2/ja active Active
- 2007-08-21 US US11/842,930 patent/US7902189B2/en active Active
- 2007-08-21 BR BRPI0715888-2A patent/BRPI0715888B1/pt active IP Right Grant
- 2007-08-21 MX MX2009001946A patent/MX2009001946A/es active IP Right Grant
- 2007-08-21 KR KR1020097005572A patent/KR101438245B1/ko active IP Right Grant
- 2007-08-22 TW TW096131156A patent/TWI406863B/zh active
- 2007-08-22 CL CL200702448A patent/CL2007002448A1/es unknown
- 2007-08-22 SA SA7280461A patent/SA07280461B1/ar unknown
- 2007-08-23 AR ARP070103751A patent/AR062503A1/es active IP Right Grant
-
2009
- 2009-01-28 IL IL196775A patent/IL196775A/en active IP Right Grant
- 2009-01-29 NO NO20090443A patent/NO342383B1/no not_active IP Right Cessation
- 2009-02-23 CO CO09017881A patent/CO6150164A2/es unknown
-
2011
- 2011-01-26 US US13/014,275 patent/US8101602B2/en active Active
- 2011-11-30 US US13/307,342 patent/US8435985B2/en active Active
-
2013
- 2013-03-14 JP JP2013051772A patent/JP5629343B2/ja active Active
- 2013-04-09 US US13/859,270 patent/US9102670B2/en active Active
-
2015
- 2015-06-08 US US14/733,257 patent/US9717736B2/en active Active
-
2017
- 2017-04-21 HR HRP20170627TT patent/HRP20170627T1/hr unknown
- 2017-04-25 CY CY20171100457T patent/CY1119381T1/el unknown
- 2017-06-19 US US15/626,282 patent/US10034884B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0715888A2 (pt) | composto ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, mÉtodos para produzir um efeito inibitàrio de mtor e um efeito anti-cÂncer em um animal de sangue quente e para tratar doenÇas em um animal de sangue quente | |
BRPI0821274A2 (pt) | composto ou um sal, ou pró-droga farmaceuticamente aceitável do mesmo, uso do mesmo, método para tratar uma doença em um animal de sangue quente, e, composição farmacêutica | |
BRPI0617241A2 (pt) | composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo | |
BRPI0814688A2 (pt) | composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar doenças, e, composição farmacêutica | |
BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI0811534A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo. | |
BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
BRPI0811542A2 (pt) | Composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e para tratar ou prevenir uma patologia relacionada com abeta em um mamífero composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e, para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
BRPI0913212A2 (pt) | composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato | |
BRPI0615157A2 (pt) | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
BRPI0607775A2 (pt) | conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença | |
BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
BRPI0618845A2 (pt) | composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
BRPI0812738A2 (pt) | Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano | |
BRPI0712516A2 (pt) | compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0607545A2 (pt) | composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
BRPI0808034A2 (pt) | Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel. | |
BRPI0907162A2 (pt) | Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: KUDOS PHARMACEUTICALS LIMITED (GB) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |